Keros Therapeutics Inc (NASDAQ: KROS) is -8.72% lower on its value in year-to-date trading and has touched a low of $9.12 and a high of $72.37 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KROS stock was last observed hovering at around $14.26 in the last trading session, with the day’s gains setting it 0.19%.
Currently trading at $14.45, the stock is 16.72% and 23.88% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 1.33% at the moment leaves the stock -59.22% off its SMA200. KROS registered -73.33% loss for a year compared to 6-month loss of -75.74%. The firm has a 50-day simple moving average (SMA 50) of $11.6643 and a 200-day simple moving average (SMA200) of $35.4323.
The stock witnessed a 33.92% gain in the last 1 month and extending the period to 3 months gives it a 27.76%, and is 4.03% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.23% over the week and 6.17% over the month.
Keros Therapeutics Inc (KROS) has around 169 employees, a market worth around $586.83M and $3.55M in sales. Profit margin for the company is -5277.55%. Distance from 52-week low is 58.44% and -80.03% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.84%).
with sales reaching $56.65M over the same period.The EPS is expected to grow by 9.93% this year, but quarterly earnings will post 1,451.57% year-over-year. Quarterly sales are estimated to grow 68,147.53% in year-over-year returns.
Keros Therapeutics Inc (KROS) Top Institutional Holders
226.0 institutions hold shares in Keros Therapeutics Inc (KROS), with institutional investors hold 119.97% of the company’s shares. The shares outstanding are 40.55M, and float is at 32.87M with Short Float at 13.41%. Institutions hold 117.07% of the Float.
The top institutional shareholder in the company is FMR LLC with over 4.72 million shares valued at $215.69 million. The investor’s holdings represent 13.073% of the KROS Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 2.51 million shares valued at $114.86 million to account for 6.9613 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 1.76 million shares representing 4.8669% and valued at over $80.3 million, while ALKEON CAPITAL MANAGEMENT LLC holds 4.4287 of the shares totaling 1.6 million with a market value of $73.07 million.
Keros Therapeutics Inc (KROS) Insider Activity
The most recent transaction is an insider purchase by ADAR1 Capital Management, LLC, the company’s 10% Owner. SEC filings show that ADAR1 Capital Management, LLC bought 934,258 shares of the company’s common stock on Apr 09 ’25 at a price of $10.13 per share for a total of $9.46 million. Following the purchase, the insider now owns 4.39 million shares.
Keros Therapeutics Inc disclosed in a document filed with the SEC on Aug 13 ’24 that GORDON CARL L (Director) sold a total of 250,000 shares of the company’s common stock. The trade occurred on Aug 13 ’24 and was made at $44.01 per share for $11.0 million. Following the transaction, the insider now directly holds 0.12 million shares of the KROS stock.
Still, SEC filings show that on Aug 13 ’24, ORBIMED ADVISORS LLC (Director) disposed off 250,000 shares at an average price of $44.01 for $11.0 million. The insider now directly holds 119,522 shares of Keros Therapeutics Inc (KROS).
